Keyphrases
Oropharyngeal Squamous Cell Carcinoma (OPSCC)
100%
High-risk Human Papillomavirus (HR-HPV)
100%
Chemoradiotherapy
100%
Programmed Death-ligand 1 (PD-L1)
100%
Immune Response
33%
Antigen-specific T Cell Response
33%
CD4+ T Cells
33%
Immunocyte
33%
HPV16 E7
33%
HPV-related Oropharyngeal Cancer
33%
PD-1 Expression
33%
Flow Cytometry
16%
Specific T Cells
16%
T Cell Assay
16%
CD4+
16%
Immunosuppression
16%
T Cell Response
16%
Standard of Care
16%
Treatment-related
16%
CD8+ T Cells
16%
Standard-of-care Therapy
16%
Induction Chemotherapy
16%
Viral Antigens
16%
PD-1 Blockade
16%
Concurrent Chemoradiotherapy
16%
Blocking Agent
16%
In Vitro Production
16%
Stage III-IV
16%
Myeloid-derived Suppressor Cells
16%
Blocking Antibodies
16%
Peptide Pools
16%
Circulating T Cells
16%
Regulatory T Cell(Treg)
16%
Anti-PD-1 Antibody
16%
E7 Peptide
16%
Immunology and Microbiology
Upregulation
100%
Wart Virus
100%
T Cell
83%
T-Helper Cell
50%
Immune Response
33%
Regulatory T Cell
33%
Blocking Antibody
33%
Immunotherapy
16%
Cell Assay
16%
Cytotoxic T-Cell
16%
Immunosuppression
16%
Virus Antigen
16%
Human Papillomavirus Type 16
16%
Myeloid-Derived Suppressor Cell
16%